Interactions between asthma and the COVID-19 pandemic
DOI:
https://doi.org/10.12775/JEHS.2022.12.11.047Keywords
COVID-19, asthma, SARS-CoV-2 pandemicAbstract
ABSTRACT
Introduction: The COVID-19 pandemic has been accompanying us in our daily lives for more than 2.5 years and so far there are no indications that it will leave us soon. Updating information and knowledge about it is therefore still incredibly important. Sars-CoV-2 is a virus with a high affinity for the respiratory system, so it is worth tracing its correlations with one of the more common lung diseases, asthma. Patients with this disease are concerned about whether they are at risk of contracting COVID-19 more frequently and severely, whether they face a higher risk of death if infected and how the pandemic will affect exacerbations of their underlying disease. For physicians who encounter the virus on a daily basis, it is important to know how well to manage asthmatic patients if COVID-19 is confirmed in them.
State of knowledge: In medicine, not everything is clear-cut. Much depends on our patient's age, condition and other comorbidities. And also on his/her adherence to medical advice, type and degree of asthma control. In this article, we will address all these aspects and summarise the current knowledge on the interplay between COVID-19 and asthma.
Conclusions: With the review of recent reports collected here, it can be thought that asthma is not an independent factor for either a higher frequency or severity of COVID-19, but neither does it affect the higher risk of death with Sars-CoV-2 infection. In terms of treatment, it is important not to interrupt the current therapy and to maintain good asthma control. This is the most optimal treatment and reduces the risk of severe COVID-19. Drugs registered for the treatment of asthma are safe and, moreover, it has been suggested that corticosteroids protect against infection to some extent.
References
Michał Pirożyński, Centrum Alergologii, Pneumonologii i Medycyny Ratunkowej, Ośrodek Symulacji CMKP w Warszawie , Asthma during infection with particular attention to the COVID-19 pandemic, Alergoprofil 2020, Vol. 16, Nr 4, 41-48
Robert Flisiak , Andrzej Horban, Jerzy Jaroszewicz , Dorota Kozielewicz , Agnieszka Mastalerz-Migas , Radosław Owczuk , Miłosz Parczewski , Małgorzata Pawłowsk , Anna Piekarsk , Krzysztof Simon, Krzysztof Tomasiewicz, Dorota Zarębska-Michaluk, Zalecenia postępowania w zakażeniach SARS-CoV-2 Polskiego Towarzystwa Epidemiologów i Lekarzy Chorób Zakaźnych, na dzień 23 lutego 2022
Anna Romaszko-Wojtowicz, Katedra Pulmonologii, Szkoła Zdrowia Publicznego, Collegium Medicum, Uniwersytet Warmińsko-Mazurski w Olsztynie, Pathogenesis and treatment of asthma and the course of COVID-19 disease, Almanach, Vol.16 NR 2´ 2021
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2020. www.ginaasthma.org (access: 21.11.2020)
Samoliński, Bolesław, et al. "Epidemiologia chorób alergicznych w Polsce (ECAP)." Alergologia Polska-Polish Journal of Allergology 1.1 (2014): 10-18.
Adir Y, Saliba W, Beurnier A, Humbert M. Asthma and COVID-19: an update. Eur Respir Rev. 2021 Dec 15;30(162):210152. doi: 10.1183/16000617.0152-2021. PMID: 34911694; PMCID: PMC8674937.
Ewa Niżankowska-Mogilnicka, Grażyna Bochenek, Piotr Gajewski, Filip Mejza https://www.mp.pl/interna/chapter/B16.II.3.7.13 sierpnia 2021
Choi HG, Wee JH, Kim SY, et al. Association between asthma and clinical mortality/ morbidity in COVID-19 patients using clinical epidemiologic data from Korean Disease Control and Prevention. Allergy. 2021 Mar;76(3):921-924. doi: 10.1111/all.14675
Peters MC, Sajuthi S, Deford P, et al. COVID-19 related genes in sputum cells in asthma: relationship to demographic features and corticosteroids. Am J Respir Crit Care Med 2020; 202: 83–90. doi:10.1164/rccm.202003-0821OC
Kaye L, Theye B, Smeenk I et al. Changes in medication adherence among patients with asthma and COPD during the COVID-19 pandemic. J Allergy Clin Immunol Pract. 2020; 8(7): 2384-5
Wang Y, Chen J, Chen W et al. Does Asthma Increase the Mortality of Patients with COVID-19?: A Systematic Review and Meta-Analysis. Int Arch Allergy Immunol. 2020: 1-7
Jerzy Kruszewski Klinika Chorób Infekcyjnych i Alergologii CSK MON WIM w Warszawie; kierownik: dr hab. med. Andrzej Chciałowski, Asthma and allergic diseases and COVID 19, LEKARZ WOJSKOWY 1/2021, 28-35.
Cameron B. Morrisona, Caitlin E. Edwardsb, Kendall M. Shaffera , Kenza C. Arabaa , Jason A. Wykoffa , Danielle R. Williamsc , Takanori Asakuraa , Hong Danga , Lisa C. Mortona , Rodney C. Gilmorea , Wanda K. O’Neala , Richard C. Bouchera , Ralph S. Baricb,c , and Camille Ehrea, SARS-CoV-2 infection of airway cells causes intense viral and cell shedding, two spreading mechanisms affected by IL-13, PNAS 2022 Vol. 119 No. 16 e2119680119, https://doi.org/10.1073/pnas.2119680119
Terry PD, Heidel RE, Dhand R, Asthma in adult patients with COVID-19: prevalence and risk of severe disease. Am J Respir Crit Care Med 2021; 203: 893–905. doi:10.1164/rccm.202008-3266OC
Liu S, Cao Y, Du T, et al. Prevalence of comorbid asthma and related outcomes in COVID-19: a systematic review and meta-analysis. J Allergy Clin Immunol Pract 2021; 9: 693–701. doi:10.1016/j.jaip.2020.11.054
Bloom CI, Drake TM, Docherty AB, et al. Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respir Med 2021; 9: 699–711doi:10.1016/S2213-2600(21)00013-8
GINA Global Strategy for Asthma Management and Prevention, GINA guidance about COVID-19 and asthma Updated 30 March 2021.
Marek L. Kowalski , Zbigniew Bartuzi , Anna Bręborowicz , Magdalena Czarnecka-Operacz , Jerzy Kruszewski , Marek Kulus , Marcin Moniuszko , Marek Niedoszytko , Marita Nittner-Marszalska , Roman J. Nowicki, Barbara Rogala, Maciej Chałubiński w ramach Sekcji PTA „Mikrobiom, infekcje a alergia” Stanowisko grupy ekspertów Polskiego Towarzystwa Alergologicznego w sprawie postępowania u chorych na astmę i choroby alergiczne w okresie pandemii SARS-CoV-2 Alergologia Polska – Polish Journal of Allergology 2020; 7, 2: 57–63 doi: https://doi.org/10.5114/pja.2020.94606
Wypowiedz Prof. dr hab. Piotr Kuna, kierownika II Katedry Chorób Wewnętrznych UM w Łodzi dla PAP z 07.11.21 https://www.pap.pl/aktualnosci/news%2C992554%2Cprofesor-kuna-sterydy-wziewne-redukuja-ryzyko-ciezkiego-przebiegu-covid-19
CDC Centers for Disease Control and Prevention. Coronaviurs Disease 2019 (COVID-19) Situation Summary. https://www.cdc. gov/coronavirus/2019-ncov/index.html.
WHO director-general’s opening remarks at the media briefing on COVID-19 – 11 March 2020 https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
Wojciech J. Piotrowski, Adam Barczyk, Andrzej Chciałowski, Joanna Chorostowska-Wynimko, Małgorzata Czajkowska-Malinowska, Aleksander Kania, Maciej Kupczyk, Krzysztof Sładek, Marek Kulus, Paweł Śliwiński, Stanowisko Polskiego Towarzystwa Chorób Płuc i Polskiego Towarzystwa Alergologicznego dotyczące leczenia powikłań płucnych u chorych po przebytym zakażeniu SARS-CoV-2, Alergologia Polska – Polish Journal of Allergology 2021; 8, 3: 101–129 doi: https://doi.org/10.5114/pja.2021.109379
Izquierdo JL, Almonacid C, González Y, et al. The impact of COVID-19 on patients with asthma. Eur Respir J 2021; 57: 2003142 doi:10.1183/13993003.03142-2020
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Klara Iwaniszyn-Zapołoch, Anna Małek, Olga Wysokińska, Karolina Zadrożna, Krystian Cholewa, Justyna Żyga
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 328
Number of citations: 0